Valuation: Orion Oyj

Market Cap 11.41B 13.16B 10.62B 9.76B 18.44B 1,255B 18.73B 125B 49.17B 625B 49.39B 48.31B 2,071B P/E 2026 *
20.2x
P/E 2027 * 17.3x
Enterprise Value 11.3B 13.03B 10.52B 9.67B 18.26B 1,243B 18.55B 124B 48.71B 619B 48.93B 47.86B 2,052B EV / Sales 2026 *
5.4x
EV / Sales 2027 * 4.69x
Free-Float
90.5%
Yield 2026 *
2.38%
Yield 2027 * 2.66%
1 day+4.81%
6 months+1.78%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37
Extreme 37
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 13.12B
-0.53%-3.12%+51.15%+150.58% 1,030B
+0.21%-1.13%+53.26%+46.92% 617B
-2.51%-2.33%+32.56%+66.35% 455B
+0.06%+1.17%+36.21%+31.25% 350B
-0.14%-0.83%+33.24%+40.28% 299B
-0.69%-0.44%+9.86%+14.23% 265B
-7.37%-4.31%-5.69%-41.99% 225B
-0.64%+3.68%+27.80%+62.95% 209B
-0.82%-0.50%+13.46%+69.41% 163B
Average -0.37%+4.83%+27.98%+48.89% 401.41B
Weighted average by Cap. -0.40%+4.87%+36.61%+70.85%

Financials

2026 *2027 *
Net sales 2.09B 2.41B 1.95B 1.79B 3.38B 230B 3.44B 22.97B 9.02B 115B 9.06B 8.87B 380B 2.35B 2.71B 2.19B 2.01B 3.8B 259B 3.86B 25.82B 10.14B 129B 10.19B 9.97B 427B
Net income 566M 652M 526M 484M 914M 62.22B 928M 6.21B 2.44B 30.99B 2.45B 2.4B 103B 651M 750M 606M 557M 1.05B 71.59B 1.07B 7.14B 2.8B 35.66B 2.82B 2.76B 118B
Net Debt -107M -124M -99.81M -91.71M -173M -11.79B -176M -1.18B -462M -5.87B -464M -454M -19.46B -369M -425M -343M -315M -596M -40.54B -605M -4.04B -1.59B -20.19B -1.6B -1.56B -66.91B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
81.10EUR
Average target price
76.50EUR
Spread / Average Target
-5.67%

Quarterly revenue - Rate of surprise